Kaplan Johanne 4

What Happened

• Johanne Kaplan, Chief Development Officer of ProMIS Neurosciences (PMN), was granted a derivative award of 50,000 shares (reported as an acquisition at $0.00) on 2026-05-20. The filing treats this as an option-style award; no cash was paid at grant.

Key Details

• Transaction date: 2026-05-20; filing date: 2026-05-22 (filed within the typical two-business-day Form 4 window).
• Consideration: $0.00 listed at grant (derivative award); total reported acquisition value = $0.
• Vesting: The award "shall vest ratably over four years," subject to continued service (footnote in filing).
• Shares owned after transaction: Not specified in the summary data provided in this notice.
• Filing timeliness: Appears timely (no late filing flag reported).

Context

• This was a grant of a derivative award (an option-style award per the footnote). Such grants typically vest over time and require future exercise (if options) to convert to shares; no immediate sale occurred. Grants to executives are common as compensation/retention and are not by themselves definitive signals of buying or selling.